Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666053 | 0.98 | CYP1A2 (0.41) | CYP1A2CHRM5ADRA2CHRH3ACHE | |
| SCHEMBL4666036 | 0.96 | GNAO1 (0.35) | CYP1A2CHRM5ADRA2CHRH3ACHE | |
| SCHEMBL4664113 | 0.92 | HRH3 (0.43) | CYP1A2CHRM5HRH3ACHEGNAO1 | |
| SCHEMBL4666482 | 0.90 | HRH3 (0.46) | CYP1A2CHRM5ADRA2CHRH3ACHE | |
| SCHEMBL4667708 | 0.88 | GNAO1 (0.40) | CYP1A2CHRM5HRH3ACHEGNAO1 | |
| SCHEMBL4665995 | 0.83 | ALDH1A1 (0.44) | CYP1A2ALDH1A1POLB | |
| SCHEMBL4383518 | 0.82 | CHRM5 (0.39) | CYP1A2CHRM5ADRA2CHRH3ACHE | |
| SCHEMBL4666493 | 0.82 | KDM1A (0.33) | GNAO1 | |
| SCHEMBL4293849 | 0.81 | SLC18A3 (0.42) | CHRM5HRH3ACHEGNAO1ALDH1A1 | |
| SCHEMBL4378807 | 0.80 | CHRM5 (0.43) | CYP1A2CHRM5ADRA2CHRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-20060148819-A1 | Chemical compounds | HENNEQUIN LAURENT F A | 2006-07-06 | — | — | US | disclosed |
| US-6887874-B2 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20030212055-A1 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| US-20030207878-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | CYP1A2 1059/4885CHRM5 1292/4885ADRA2C 1602/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | CYP1A2 1687/4885CHRM5 1885/4885ADRA2C 1149/4885 |
| US-20060148819-A1 | Chemical compounds | VEGFA, NOS3, FLT4 | CYP1A2 249/4885CHRM5 220/4885ADRA2C 223/4885 |
| US-20030207878-A1 | Chemical compounds | CYP3A7, HTR3C, CNR1 | CYP1A2 65/4885CHRM5 89/4885ADRA2C 52/4885 |
| US-20030212055-A1 | Cinnoline compounds | VEGFA, PGF, CCR7 | CYP1A2 859/4885CHRM5 757/4885ADRA2C 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.